Relmada Therapeutics Inc (NAS:RLMD)
$ 0.3614 -0.0182 (-4.79%) Market Cap: 10.90 Mil Enterprise Value: -43.21 Mil PE Ratio: 0 PB Ratio: 0.23 GF Score: 33/100

Relmada Therapeutics Inc at Goldman Sachs Global Healthcare Conference Transcript

Jun 14, 2022 / 05:40PM GMT
Release Date Price: $17.09 (+1.18%)
Andrea R. Tan
Goldman Sachs Group, Inc., Research Division - Research Analyst

Well, thanks, everyone, for joining us. We're really pleased to have the team from Relmada with us, Sergio Traversa, CEO; and Caroline Cotton, Communications Manager. With that, Sergio, maybe we'll start with the pivotal [Rev3 Phase III] trials coming this year.

But before we start with that, maybe just for people who may not be as familiar, if you could remind us on the profile that you've seen so far with REL-1017 -- will make you so excited about it.

Sergio Traversa
Relmada Therapeutics, Inc. - CEO & Director

Sure. Well, Andrea, first of all, thank you for the invitation and thanks, Goldman Sachs, and good morning all good afternoon for the people that are on the other side on the East Coast. And profile of REL-1017. We're talking about CNS, we are talking about depression and both monotherapy and adjuvant or adjunctive treatment of depression.

The profile, what we have seen in Phase II is the data that we have in our hands that we hope to repeat in the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot